Up next

Autoplay

Dr. Andrew Zelenetz on the Impact of Rituximab in Lymphoma

1 Views • 08/26/25
Share
Side Effects
Side Effects
Subscribers
0

Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab (Rituxan) has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

For more on lymphoma and other hematologic malignancies, visit http://www.onclive.com/special....ty/hematologic-cance

Show more
0 Comments sort Sort By

Up next

Autoplay